Investment & Markets
CMA invites comment on Intersurgical's planned purchase of Teleflex acute care and urology units
The CMA is seeking views on Intersurgical AG's anticipated acquisition of two Teleflex businesses. Armira Capital and TA Associates are due to acquire control of Intersurgical. Comments close on 3 November 2026.

The Competition and Markets Authority (CMA) has opened an invitation to comment on the anticipated acquisition by Intersurgical AG of the acute care and interventional urology businesses of Teleflex Incorporated. The case page was published and the case opened on 20 October 2026. The CMA lists the case type as mergers, the case state as open and the market sector as healthcare and medical equipment.
According to the CMA, control over Intersurgical AG will be acquired by Armira Capital and TA Associates following the transaction. The page does not describe the products concerned, the parties' UK activities, a transaction value or an expected completion date, and it does not say whether the CMA has identified any competition concerns.
What the CMA is asking
The invitation to comment runs from 20 October to 3 November 2026. The CMA said it wants initial views from any interested party on the impact the transaction could have on competition in the UK. Written representations about competition issues should be submitted by the closing date to one of two CMA email addresses given on the page, including the case mailbox intersurgical.teleflex@cma.gov.uk.
The CMA stressed that it has not yet launched its formal investigation. It described the invitation as the first part of its information-gathering process, and said the case page will be updated when it formally commences its phase 1 investigation. The published statutory timetable currently shows only the invitation to comment, covering 20 October 2026 to 3 November 2026, within phase 1.
The CMA also said it has received the necessary information from the parties to commence pre-notification.
On data handling, the CMA said that respondents' names and contact details are personal data. It said it processes them so that it can contact respondents again if it needs further help or information for its merger work under Part 3 of the Enterprise Act 2002.
Why it matters
The case shows the CMA examining a transaction in healthcare and medical equipment that also involves two named private investment firms taking control of the acquirer. Suppliers, customers and competitors in the affected product areas have a short window to give the CMA their views, and the outcome of any formal phase 1 review could affect deal timing. The source does not say which products or UK markets are of interest, so the scope of any concerns is not yet clear.
Source: CMA cases


